viewKazia Therapeutics Ltd

Kazia Therapeutics wins ANZLF Trans-Tasman Innovation and Growth award

The awards are run by the Australian New Zealand Leadership Forum which brings senior businesses and government leaders together to help both nations prosper in the global economy.

Kazia Therapeutics Ltd - Kazia Therapeutics wins ANZLF Trans-Tasman Innovation and Growth award
Kazia is making significant progress in the clinical testing of lead candidate GDC-0084

Kazia Therapeutics Ltd (ASX:KZA) is a winner in the 2019 Australian and New Zealand Leadership Forum (ANZLF) Trans-Tasman Innovation and Growth Awards presented yesterday in Auckland, New Zealand.

The awards celebrate the innovation, growth and impact of emerging businesses in Australia and New Zealand and were presented by New Zealand Prime Minister Jacinda Arden and Australian Minister for Trade, Tourism and Investment Simon Birmingham.

Kazia was recognised for being an innovative, product-focused and agile company with the award reflecting its progress in the clinical testing of its lead candidate, GDC-0084.

The investigational new drug, GDC-0084 is being developed by the company to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults, as well as other forms of brain cancer.

Completion of phase-I study

The company recently revealed that St Jude Children’s Research Hospital successfully completed the first stage of its ongoing phase-I study of GDC-0084 in diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas.

Diffuse midline gliomas, including DIPG, represent one of the most aggressive childhood cancers and several hundred new cases are diagnosed in the US each year.

Median life expectancy from diagnosis is estimated to be 9-11 months and there is no approved pharmacological therapy.

Quick facts: Kazia Therapeutics Ltd

Price: 0.96 AUD

Market: ASX
Market Cap: $69.28 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kazia Therapeutics Ltd named herein, including the promotion by the Company of Kazia Therapeutics Ltd in any Content on the Site, the Company...


Kazia Therapeutics CEO hails Fast Track Designation for Paxalisib

Kazia Therapeutics Ltd's (ASX:KZA) (NASDAQ:KZIA) Dr James Garner caught up with Proactive's Andrew Scott following the news it's been awarded US Food and Drug Administration (FDA) Fast Track Designation (FTD) for Paxalisib for the treatment of glioblastoma – the most common and aggressive form...

on 08/21/2020

2 min read